JOHNSON JOHN 4

What Happened

• John Johnson, a director of Axogen, received 14,150 shares of common stock on June 19, 2026 when restricted stock units (RSUs) vested and converted into shares. The transaction is reported as an exercise/conversion of a derivative (code M) and the shares were acquired at $0.00 (no cash paid). The grant underlying these RSUs was an annual director equity award valued at $150,000 on the grant date.

Key Details

• Transaction date: June 19, 2026 (reported on Form 4 filed June 23, 2026)
• Price: $0.00 per share (acquisition via RSU vesting/settlement)
• Shares received: 14,150 shares (reported as conversion of derivative and resulting share issuance)
• Shares owned after transaction: Not disclosed in the provided filing details
• Footnotes: F1 — reflects RSUs that vested on June 19, 2026; F2 — each RSU equals one share; F3 — annual director grant valued at $150,000, vesting on the one‑year anniversary of the grant date
• Filing timeliness: Reported June 23, 2026 for a June 19 transaction; this filing date appears to meet the standard Section 16 reporting window.

Context

• This was a vesting/settlement of an equity award (RSUs), not an open‑market purchase or sale. Such awards are routine compensation for directors and do not, by themselves, indicate a buy or sell sentiment. No immediate sale or cashless exercise was reported in this filing.